Department of Diabetes and Metabolism Internal Medicine, Kobari General Hospital, 29-1, Yokouchi, Noda city, Chiba 278-8501, Japan.
Diabetes Res Clin Pract. 2013 Oct;102(1):e8-e12. doi: 10.1016/j.diabres.2013.07.010. Epub 2013 Aug 9.
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1α level.
二肽基肽酶-4 抑制剂（DPP-4Is）在抑制肠促胰岛素激素失活的同时，也会影响免疫系统，因为 CD26/DPP-4 参与免疫调节。本研究表明，使用 DPP-4Is 治疗 2 型糖尿病患者可能会引起关节症状，并降低血浆 SDF-1α 水平。
